Introduction {#s1}
============

Globally, hepatocellular carcinoma (HCC) is among the most prevalent malignant tumors [@pone.0029179-Bosch1]. Of all cancers, HCC has had the highest and second highest mortality rates in males and in females, respectively, since the early 1980s [@pone.0029179-Kao1]. In Taiwan, the incidence rates of HCC have steadily increased in the past two decades: the respective age-standardized incidence rates for men and women increased from 55.8 and 22.3 per 100,000 in 2002 to 62.1 and 25.6 per 100,000 in 2007 [@pone.0029179-Taiwan1]. In 2009, HCC also comprised 38.0% and 14.9% of all cancer-related deaths in men and women in Taiwan, respectively [@pone.0029179-Department1]. Hepatic resection is the most common treatment modality for HCC and is among the most effective interventions [@pone.0029179-Hanazaki1]--[@pone.0029179-Lee1] for achieving long-term survival. However, even after undergoing hepatic resection, patients with HCC may still have very poor prognoses because of the low survival and high recurrence rates associated with this procedure [@pone.0029179-Zhang1]. Therefore, the aim of this study was to construct an accurate and effective model for predicting disease-free survival in HCC patients who have received hepatic resection. An improved model would enable further development of computerized medical decision support systems for aiding surgeons and healthcare institutions in constructing guidelines for interpreting clinical outcomes. Although previous studies [@pone.0029179-Ercolani1], [@pone.0029179-Yeh1] have examined disease-free survival rates at various endpoints, none have evaluated the accuracy of models for predicting disease-free survival after hepatic resection in HCC patients at different endpoints (i.e., 1, 3, and 5 years after resection).

Recently, machine-learning and statistical methods have been applied to develop prediction models for clinical diagnosis and treatment, e.g., artificial neural networks (ANNs), logistic regression (LR) and decision tree (DT) (see, e.g., [@pone.0029179-Li1]--[@pone.0029179-Liew1] and the references therein). Clinical application of these prediction models can potentially improve diagnostic accuracy, treatment decisions, and efficiency in using limited health care resources [@pone.0029179-Li1].

Artificial neural networks have proven particularly effective for nonlinear mapping based on human knowledge and are attracting interest for use in solving complex classification problems [@pone.0029179-Tsai1], [@pone.0029179-Ho1]. A multilayer ANN containing layers of simple computing nodes is analogous to brain neural networks that can accurately approximate nonlinear continuous functions and reveal previously unknown relationships between given input and output variables [@pone.0029179-Ho2], [@pone.0029179-Ho3]. Because of their unique structure, ANNs can learn by using algorithms such as backpropagation algorithm and evolutionary algorithm [@pone.0029179-Tsai2], [@pone.0029179-Ho4]. Potential medical applications of ANNs include problems in which the relationship between independent variables and clinical outcome are poorly understood [@pone.0029179-Robinson1]. Because ANNs are capable of self training with minimal human intervention, many studies of large epidemiology databases have, in addition to traditional statistical methods, used ANNs for further insight into the interrelationships among variables. However, since few studies have compared performance between ANNs and other modeling techniques such as LR and DT, these interrelationships are still unclear [@pone.0029179-Terrina1]. Our objective was to fill a gap in the current literature by comparing the predictive performance of three modeling techniques so that improved models for predicting 1-, 3- and 5-year disease-free survival can be implemented in knowledge-based computer programs and in medical decision support systems.

This study therefore constructed a database of HCC patients who had received hepatic resection between 2000 and 2007 at either of two hospitals in Kaohsiung, Taiwan: Kaohsiung Medical University Hospital and Yuan\'s Hospital. The database included demographic, clinical, surgical and outcome data. An ANN model, an LR model, and a DT model were constructed to predict 1-, 3- and 5-year disease-free survival. The three models were based on data for 80% of the cases, which were randomly selected. The remaining 20% of the cases were then used for performance tests of the three models. Predictive accuracy was compared by areas under receiver operating characteristics curve (AUROC) analyses.

Methods {#s2}
=======

Data collection and variable selection {#s2a}
--------------------------------------

The study population included 482 patients who had received liver resection for HCC and were currently disease-free. The exclusion criteria were any history of the following: (i) liver resection; (ii) treatment with radiofrequency ablation or microwave ablation; (iii) histopathological evidence of benign tumor and/or non-primary liver cancer; (iv) unavailable and/or incomplete medical history; (v) death within thirty days after surgery; (vi) tumor remaining after resection; (vii) incomplete data for key explained variables; and (viii) follow-up data for less than 1 year. Therefore, 427, 354 and 297 patients were classified into the 1-, 3- and 5-year disease-free survival groups, respectively. In each patient, medical records were reviewed by the attending physician. Data collection included demographic data, clinical features, and surgical process and outcome. Ethical approval was provided by Institutional Review Board of the Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH-IRB-990166). Patients provided written informed consent.

Patients were classified as disease-free hepatic resection survivors if no death or recurrence occurred during the 1-, 3-, or 5-year periods considered in the three survival models. In other words, survival (no event) was defined as disease-free survival after 1, 3, or 5 years. Therefore, presence of an event (death or recurrence) was coded as 1, and absence of an event (disease-free survival) was coded as 0.

First, continuous explanatory variables were transformed into categorical variables to minimize the effects of extreme values and to enhance the computing efficiency of the ANN model. The cut-off points for these variables were based on those used in previous clinical studies [@pone.0029179-Hanazaki1], [@pone.0029179-Lee1], [@pone.0029179-Yeh2]--[@pone.0029179-Sasaki1]. Low and high risk were coded as 0 and 1, respectively. The variables included BUN AST, α-fetoprotein, ALT, total bilirubin, and others. Other recoded items included TNM stage, a common prognostic index of cancer risk or severity, and ASA, a risk score for surgical procedures. The TNM stage ranges from 1 to 6, and ASA score ranges from 1 to 4. Two variables were recoded as 0 for low risk, 1 for medium risk, and 2 for high risk ([Table 1](#pone-0029179-t001){ref-type="table"}). High risk was assumed to increase the probability of recurrence (event). Second, to enhance the calculation efficiency and prediction performance of the ANN models, univariate Cox proportional hazard model was used to test relationships among potential variables. Variables with statistically significant associations (log-rank test, P\<0.05) with disease-free survival were retained to construct the ANN models ([Table 1](#pone-0029179-t001){ref-type="table"}). Finally, of the 31 input variables, the 15 statistically significant variables used to construct the ANN models were liver cirrhosis, chronic hepatitis, AST, ALT, total bilirubin, albumin, creatinine, ASA classification, Child-Pugh classification, TNM stage, tumor number, portal vein invasion, biliary invasion, surgical procedure, and post-operative complication. Age and gender were also included as control variables.

10.1371/journal.pone.0029179.t001

###### Potential input variables for prediction models (N = 482).

![](pone.0029179.t001){#pone-0029179-t001-1}

  Variables                                                                      Value                       P value
  ------------------------------------------------------------- --------------------------------------- ------------------
  Demographic characteristics                                                                           
  Age (years)[a](#nt101){ref-type="table-fn"}                         0:⩽65, 1:\>65 (mean = 57.7)              0.43
  Gender[a](#nt101){ref-type="table-fn"}                                  0: male, 1: female                   0.43
  Clinical features                                                                                     
  Comorbidity                                                                0: no, 1: yes                     0.16
  Liver cirrhosis[b](#nt102){ref-type="table-fn"}                            0: no, 1: yes                   \<0.001
  Chronic hepatitis[b](#nt102){ref-type="table-fn"}                 0: no, 1: HBV, 2: HCV, 3: HBCV       0.29, 0.02, 0.01
  α-Fetoprotein (ng/ml)                                                     0:⩽100, 1:\>100                    0.10
  AST (U/L)[b](#nt102){ref-type="table-fn"}                                  0:⩽80, 1:\>80                   \<0.001
  ALT (U/L)[b](#nt102){ref-type="table-fn"}                                  0:⩽80, 1:\>80                   \<0.001
  Total bilirubin (mg/dl)[b](#nt102){ref-type="table-fn"}                   0:⩽1.0, 1:\>1.0                    0.01
  Albumin (g/dl)[b](#nt102){ref-type="table-fn"}                            0:\>3.5, 1:⩽3.5                  \<0.001
  BUN (mg/dl)                                                                0:⩽21, 1:\>21                     0.44
  Creatinine (mg/dl)[b](#nt102){ref-type="table-fn"}                        0:⩽1.4, 1:\>1.4                    0.09
  Platelet (10^3^/µl)                                                       0:\>150, 1:⩽150                  \<0.001
  Prothrombin time (%)                                                       0:⩽80, 1:\>80                     0.61
  ICGR~15~ (%)                                                               0:⩽15, 1:\>15                     0.15
  ASA classification[b](#nt102){ref-type="table-fn"}             0: ASA = 1, 1: ASA = 2, 2: ASA = 3, 4      0.01, 0.13
  Child-Pugh classification[b](#nt102){ref-type="table-fn"}                  0: A, 1: B,C                      0.01
  TNM stage[b](#nt102){ref-type="table-fn"}                      0: I, 1: II, 2: IIIa, IIIb, IIIc, IV    \<0.001, \<0.001
  Tumor number[b](#nt102){ref-type="table-fn"}                          0: single, 1: multiple               \<0.001
  Tumor size (cm)                                                             0:⩽5, 1:\>5                      0.08
  Portal vein invasion[b](#nt102){ref-type="table-fn"}                       0: no, 1: yes                   \<0.001
  Biliary invasion[b](#nt102){ref-type="table-fn"}                           0: no, 1: yes                     0.02
  Surgical process and outcome                                                                          
  Surgical procedure[b](#nt102){ref-type="table-fn"}               0: laparoscopic, 1: open surgery          \<0.001
  Extent of resection                                                     0: minor, 1: major                   0.45
  Resection margin (mm)                                                      0:\>10, 1:⩽10                     0.15
  Surgical time                                                             0:⩽180, 1:\>180                    0.34
  Blood loss (ml)                                                          0:⩽1000, 1:\>1000                   0.71
  Blood transfusion                                                          0: no, 1: yes                     0.65
  Blood transfusion (ml)                                                   0:⩽1000, 1:\>1000                   0.06
  Post-operative complication[b](#nt102){ref-type="table-fn"}                0: no, 1: yes                     0.01
  Preoperative treatment                                                     0: no, 1: yes                     0.08

: control input variable.

: significant input variable.

Training and validation data sets {#s2b}
---------------------------------

From each of the three survival groups, 80% of the cases were assigned to training groups for developing the ANN, LR and DT models, and the remaining 20% were assigned to validation groups for performance tests of the models for predicting 1-, 3-, and 5-year disease-free survival. That is, of the 427 1-year cases, 342 were used for training, and 85 were used for validation; of the 354 3-year cases, 283 were used for training, and 71 were used for validation; of the 297 5-year cases, 238 were used for training, and 59 were used for validation ([Table 2](#pone-0029179-t002){ref-type="table"}). [Table 2](#pone-0029179-t002){ref-type="table"} shows that (i) the specific data contained in each clinical case were summarized with their descriptive characteristics for 1-, 3-, and 5-year disease-free survival. For example, 245 (71.6%) patients were aged older than 65 years and 97 (28.4%) patients were aged 65 years or younger. In the 1-year training group, 252 (73.7%) patients were male, and 90 (26.3%) patients were female; (ii) at 1-, 3-, and 5 years after the resection procedure, post-resection events (i.e., recurrence or death) had occurred in 155 (36.3%), 226 (63.8%) and 247 (83.2%) patients; and (iii) in all three survival models, the effects of input variables did not significantly differ between training and validation (P\>0.05), which confirmed the reliability of the data selection.

10.1371/journal.pone.0029179.t002

###### Comparison of clinical features between training and validation groups.

![](pone.0029179.t002){#pone-0029179-t002-2}

  Variables                           Definitions        1-year(N = 427)               3-year(N = 354)                 5-year(N = 297)                                               
  ------------------------------ ---------------------- ----------------- ------ ---- ----------------- ------- ----- ----------------- ---- ------ ------- ----- ------ ---- ------ -------
  Age                                     ⩽65                  245         71.6   67        78.8         0.181   206        72.8         54   76.1   0.578   177   74.4   40   67.8   0.308
                                          \>65                 97          28.4   18        21.2                 77         27.2         17   23.9           61    25.6   19   32.2  
  Gender                                  Male                 252         73.7   70        82.4         0.097   214        75.6         53   74.6   0.865   175   73.5   45   76.3   0.667
                                         Female                90          26.3   15        17.6                 69         24.4         18   25.4           63    26.5   14   23.7  
  Liver cirrhosis                          No                  112         32.7   37        43.5         0.062   101        35.7         18   25.4   0.099   72    30.3   21   35.6   0.428
                                          Yes                  230         67.3   48        56.5                 182        64.3         53   74.6           166   69.7   38   64.4  
  Chronic hepatitis                        No                  37          10.8   12        14.1         0.644   28          9.9         10   14.1   0.390   22    9.2    9    15.3   0.603
                                          HBV                  185         54.1   40        47.1                 145        51.2         35   49.3           119   50.0   27   45.8  
                                          HCV                  95          27.8   27        31.8                 90         31.8         18   25.4           75    31.5   18   30.5  
                                          HBCV                 25          7.3    6          7.1                 20          7.1         8    11.3           22    9.2    5    8.5   
  AST                                     ⩽80                  284         83.0   65        76.5         0.161   227        80.2         56   78.9   0.801   185   77.7   47   79.7   0.748
                                          \>80                 58          17.0   20        23.5                 56         19.8         15   21.1           53    22.3   12   20.3  
  ALT                                     ⩽80                  272         79.5   65        76.5         0.536   217        76.7         57   80.3   0.516   178   74.8   48   81.4   0.290
                                          \>80                 70          20.5   20        23.5                 66         23.3         14   19.7           60    25.2   11   18.6  
  Total bilirubin                         ⩽1.0                 246         71.9   63        74.1         0.686   203        71.7         53   74.6   0.623   166   69.7   46   78.0   0.211
                                         \>1.0                 96          28.1   22        25.9                 80         28.3         18   25.4           72    30.3   13   22.0  
  Albumin                                \>3.5                 272         79.5   66        77.6         0.702   220        77.7         55   77.5   0.960   180   75.6   45   76.3   0.918
                                          ⩽3.5                 70          20.5   19        22.4                 63         22.3         16   22.5           58    24.4   14   23.7  
  Platelet                               \>150                 169         49.4   44        51.8         0.698   130        45.9         39   54.9   0.175   107   45.0   31   52.5   0.296
                                          ⩽150                 173         50.6   41        48.2                 153        54.1         32   45.1           131   55.0   28   47.5  
  ASA Classification                       1                   90          26.3   12        14.1         0.062   79         27.9         17   23.9   0.700   67    28.2   21   35.6   0.387
                                           2                   175         51.2   51        60.0                 144        50.9         40   56.3           124   52.1   25   42.4  
                                          3, 4                 77          22.5   22        25.9                 60         21.2         14   19.7           47    19.7   13   22.0  
  Child-Pugh Classification                A                   334         97.7   83        97.6         0.994   277        97.9         68   95.8   0.314   230   96.6   58   98.3   0.504
                                          B, C                  8          2.3    2          2.4                  6          2.1         3    4.2             8    3.4    1    1.7   
  TNM Stage                                I                   200         58.5   47        55.3         0.807   159        56.2         36   50.7   0.468   124   52.1   28   47.5   0.765
                                           II                  108         31.6   30        35.3                 94         33.2         29   40.8           88    37.0   23   39.0  
                                  IIIa, IIIb, IIIc, IV         34          9.9    8          9.4                 30         10.6         6    8.5            26    10.9   8    13.6  
  Tumor no.                              Single                244         71.3   61        71.8         0.939   201        71.0         44   62.0   0.140   156   65.5   40   67.8   0.744
                                        Multiple               98          28.7   24        28.2                 82         29.0         27   38.0           82    34.5   19   32.2  
  Tumor size (cm)                          ⩽5                  268         77.2   67        77.0         0.965   204        74.7         50   73.5   0.840   154   73.0   37   69.8   0.644
                                          \>5                  79          22.8   20        23.0                 69         25.3         18   26.5           57    27.0   16   30.2  
  Portal vein invasion                     No                  277         81.0   65        76.5         0.350   227        80.2         56   78.9   0.801   184   77.3   47   79.7   0.698
                                          Yes                  65          19.0   20        23.5                 56         19.8         15   21.1           54    22.7   12   20.3  
  Biliary invasion                         No                  334         97.7   83        97.6         0.994   276        97.5         69   97.2   0.869   230   96.6   58   98.3   0.504
                                          Yes                   8          2.3    2          2.4                  7          2.5         2    2.8             8    3.4    1    1.7   
  Surgical procedure                  Laparoscopic             66          19.3   18        21.2         0.697   60         21.2         13   18.3   0.590   57    23.9   11   18.6   0.385
                                      Open surgery             276         80.7   67        78.8                 223        78.8         58   81.7           181   76.1   48   81.4  
  Post-operative complication              No                  311         90.9   78        91.8         0.810   255        90.1         63   88.7   0.732   214   89.9   50   84.7   0.258
                                          Yes                  31          9.1    7          8.2                 28          9.9         8    11.3           24    10.1   9    15.3  
  Disease-free survival status             No                  211         61.7   61        71.8         0.084   108        38.2         20   28.2   0.117   36    15.1   14   23.7   0.114
                                          Yes                  131         38.3   24        28.2                 175        61.8         51   71.8           202   84.9   45   76.3  

Modeling tools {#s2c}
--------------

The training group data were used to construct an ANN model, an LR model and a DT model. The ANN model included input, hidden, and output layers. [Figure 1](#pone-0029179-g001){ref-type="fig"} shows the three independent ANN models for 1-, 3- and 5-year disease-free survival. The input layer in each of the three models contained 17 neurons: age, gender, liver cirrhosis, chronic hepatitis, AST, ALT, total bilirubin, albumin, creatinine, ASA classification, Child-Pugh classification, TNM stage, tumor number, portal vein invasion, biliary invasion, surgical procedure, and post-operative complication. In the hidden layers, the numbers of neurons were optimized using training and validation data in a trial-and-error process to maximize predictive accuracy [@pone.0029179-Robinson1], which resulted in 30, 17 and 7 neurons in the 1-, 3- and 5-year models, respectively. The output layer in each of the three models had only one neuron representing the disease-free survival of HCC patients after hepatic resection.

![Framework of artificial neural network for the 1-, 3- and 5-year disease-free survival models.\
The input layer in each of the three models contained 17 neurons. In the hidden layers, the numbers of neurons were 30, 17 and 7 the 1-, 3- and 5-year models, respectively. The output layer in each of the three models had only one neuron representing the disease-free survival of HCC patients after hepatic resection.](pone.0029179.g001){#pone-0029179-g001}

The LR model generates the coefficients for the following formula used for logit transformation of the probability of a patient having a characteristic of interest: [@pone.0029179-Cucchetti1]. The formula used for calculating the probability of the characteristic of interest in this study, where 1 = disease-free survival status and 0 = non-disease-free survival status.

Because of its easily interpreted decision rules, the DT model with C4.5 [@pone.0029179-Samanta1] was used for classification and regression. In this model, each object in the input dataset belongs to a class. Each object is characterized by a set of attributes (variables or predictors) that may have numerical and categorical (non-numerical) values. The goal of DT is to use a training dataset with known attribute-class combinations for generating a tree structure with a rule set for correctly classifying and predicting a similar test dataset. In addition to its root and internal (non-terminal) decision nodes, a DT has a set of terminal nodes (leaves), each of which represents a class. The rules associated with the DT, from the root to each terminal node (leaf), are easily interpretable for predicting a class. The steps of the learning process are (i) using an impurity function to select the most discriminative variable for data partitioning, (ii) repeating the partitioning until the nodes are sufficiently pure for use as terminal nodes, and (iii) pruning the completed tree to avoid over-fitting [@pone.0029179-Colombet1].

The software used to construct the ANN and DT models was Waikato Environment for Knowledge Analysis (WEKA) version 3.6.0 [@pone.0029179-Witten1]. The LR model was constructed using SPSS for Windows version 6.1.

Results {#s3}
=======

For the training and validation groups, [Figs. 2](#pone-0029179-g002){ref-type="fig"} and [3](#pone-0029179-g003){ref-type="fig"}, respectively, show the receiver operating characteristics (ROC) curves for the 1-, 3- and 5-year disease-free survival models constructed using ANN, LR and DT. [Tables 3](#pone-0029179-t003){ref-type="table"} and [4](#pone-0029179-t004){ref-type="table"} show the respective AUROC curves constructed using the data shown in [Figs. 2](#pone-0029179-g002){ref-type="fig"} and [3](#pone-0029179-g003){ref-type="fig"}. For example, the AUROCs for 1-year models constructed by ANN, LR and DT were 0.977, 0.771 and 0.734, respectively. For the training data and validation data, [Tables 3](#pone-0029179-t003){ref-type="table"} and [4](#pone-0029179-t004){ref-type="table"} show the respective AUROC values, sensitivities and specificities for the 1-, 3- and 5-year disease-free survival models obtained by ANN, LR and DT. In the 1-year model for the training group, for instance, sensitivity and specificity were 0.962 and 0.916 when using ANN, 0.848 and 0.466 when using LR, and 0.948 and 0.458 when using DT, respectively. Notably, in all training groups and in most validation groups sensitivity and specificity for the 1-, 3- and 5-year models constructed using ANN were not only within acceptable limits, but were actually superior to those for models constructed using LR and DT.

![ROC curves and AUROCs for the 1-, 3- and 5-year disease-free survival models constructed for training groups using ANN, LR and DT.\
The AUROC values for 1-year (A), 3-year (B) and 5-year (C) disease-free survival were 0.977, 0.989 and 0.963 for ANN models, 0.771, 0.751 and 0.769 for LR models, and 0.734, 0.825 and 0.760 for DT models, respectively. In all disease-free survival models for training groups, AUROC values obtained by ANN were superior to those obtained by LR and DT.](pone.0029179.g002){#pone-0029179-g002}

![ROC curves and AUROCs for the 1-, 3- and 5-year disease-free survival models constructed for validation groups using ANN, LR and DT.\
The AUROC values for 1-year (A), 3-year (B) and 5-year (C) disease-free survival were 0.777, 0.774 and 0.864 for ANN models, 0.772, 0.725 and 0.736 for LR models, and 0.718, 0.561 and 0.627 for DT models, respectively. In all disease-free survival models for validation groups, AUROC values obtained by ANN were superior to those obtained by LR and DT.](pone.0029179.g003){#pone-0029179-g003}

10.1371/journal.pone.0029179.t003

###### Performance comparison of ANN, LR and DT models for predicting 1-, 3- and 5-year disease-free survival in training groups.

![](pone.0029179.t003){#pone-0029179-t003-3}

                 1-year(N = 342)                   3-year(N = 283)                   5-year(N = 238)          
  ------------- ----------------- ------- ------- ----------------- ------- ------- ----------------- ------- -------
  AUROC               0.977        0.771   0.734        0.989        0.751   0.825        0.963        0.769   0.675
  Sensitivity         0.962        0.848   0.948        0.963        0.519   0.750        0.935        0.109   0.196
  Specificity         0.916        0.466   0.458        0.931        0.789   0.811        0.979        0.958   0.979

10.1371/journal.pone.0029179.t004

###### Performance comparison of ANN, LR and DT models for predicting 1-, 3- and 5-year disease-free survival in validation groups.

![](pone.0029179.t004){#pone-0029179-t004-4}

                 1-year(N = 85)                   3-year(N = 71)                   5-year(N = 59)          
  ------------- ---------------- ------- ------- ---------------- ------- ------- ---------------- ------- -------
  AUROC              0.777        0.772   0.718       0.774        0.725   0.561       0.864        0.736   0.627
  Sensitivity        0.787        0.754   0.885       0.700        0.450   0.550       0.750        0.000   0.000
  Specificity        0.542        0.583   0.375       0.745        0.765   0.608       0.764        0.927   0.964

Discussion {#s4}
==========

Model sensitivity and specificity are important when testing whether a model can accurately recognize positive and negative outcomes. Sensitivity and specificity must also be measured to determine the proportion of false negatives or false positives produced by a model [@pone.0029179-TrticaMajnaric1]. Comparing false positive and false negative rates reveals the tendency of a model to misclassify positive patients as negative patients and vice versa [@pone.0029179-Simon1]. The ideal model has both high sensitivity and high specificity [@pone.0029179-Simon1]. In the current study, comparisons of predictive performance showed that the LR and DT models had poor sensitivity (\<40%) but high specificity (\>80%) for predicting 5-year disease-free survival in the training groups ([Table 3](#pone-0029179-t003){ref-type="table"}); the DT model had poor specificity (\<40%) but high sensitivity (\>80%) for predicting 1-year disease-free survival in the validation groups ([Table 4](#pone-0029179-t004){ref-type="table"}), and the LR and DT models had poor sensitivity (\<40%) but high specificity (\>80%) for predicting 5-year disease-free survival in the validation groups ([Table 4](#pone-0029179-t004){ref-type="table"}). Specifically, [Table 4](#pone-0029179-t004){ref-type="table"} shows that the sensitivity values for predictions of 5-year disease-free survival with LR and DT models in the validation groups were zero. The explanation is the occurrence of false positives (i.e., type I error) [@pone.0029179-TrticaMajnaric1]. That is, the LR and DT models, which had very low sensitivity, could be not used to screen for disease-free survival in HCC patients who had received hepatic resection since they lacked sufficient specificity for identifying true positives. However, sensitivity and specificity remained high in all ANN models ([Tables 3](#pone-0029179-t003){ref-type="table"} and [4](#pone-0029179-t004){ref-type="table"}). Since AUROC provides a superior performance index in addition to superior accuracy, AUROC was used to evaluate the predictive accuracy of classifiers [@pone.0029179-Fawcett1]. The AUROC of a classifier can be defined as the probability of the classifier ranking a randomly chosen positive example higher than a randomly chosen negative example [@pone.0029179-Fawcett1]. Therefore, the higher the AUROC, the higher the predictive accuracy [@pone.0029179-Ke1]. This study also used AUROC values for performance comparisons of different prediction models. For the training groups, [Table 3](#pone-0029179-t003){ref-type="table"} shows that the AUROC values for 1-, 3- and 5-year disease-free survival were 0.977, 0.989 and 0.963 for ANN models, 0.771, 0.751 and 0.769 for LR models, and 0.734, 0.825 and 0.760 for DT models, respectively. In the validation groups ([Table 4](#pone-0029179-t004){ref-type="table"}), the respective values were 0.777, 0.774 and 0.864 for ANN models, 0.772, 0.725 and 0.736 for LR models and 0.718, 0.561 and 0.627 for DT models. In all disease-free survival models, AUROC values obtained by ANN were superior to those obtained by LR and DT. Thus, the ANN models outperformed the LR and DT models in terms of predictive accuracy. The ROC curves in [Figures 2](#pone-0029179-g002){ref-type="fig"} and [3](#pone-0029179-g003){ref-type="fig"} further show that the ANN was consistently more accurate in predicting 1-, 3- and 5-year disease-free survival compared to the LR and DT models, both of which demonstrated inconsistent results. The above comparisons thus confirm that ANN outperforms both LR and DT in predicting disease-free survival in HCC patients who have received hepatic resection.

Even when only seventeen easily obtainable parameters were used, the ANN models developed in this study demonstrated acceptable accuracy. Variables that were not significantly associated with disease-free survival were intentionally omitted when constructing the ANN models. The dependent variable indicates a decision by the lead surgeon in each case to perform a surgical intervention. In predictive mode, however, it can be considered a reliable estimation of confidence in the decision to operate on a specific patient since the ANN models were trained by a large patient database from teaching hospitals with highly qualified surgeons. Moreover, omitting this variable expanded the potential applications of the resultant model to circumstances in which advanced diagnostic.

Yeh et al. [@pone.0029179-Yeh1] used multiple logistic regression to predict associations between clinicopathologic factors and \>5-year survival without recurrence in HCC patients treated with hepatectomy. Ercolani et al. [@pone.0029179-Ercolani1] also evaluated prognostic factors affecting 5-year disease-free survival after liver resection in HCC patients with cirrhosis. However, the above studies [@pone.0029179-Ercolani1], [@pone.0029179-Yeh1] focused on survival rates and predictors and did not compare the predictive accuracy of different statistical models. The current study, however, compared different statistical models in terms of accuracy in predicting 1-, 3- and 5-year disease-free survival after hepatic resection in HCC patients. The comparisons revealed that predictive accuracy significantly differed among ANNs, LRs and DTs. To our knowledge, very few studies have compared predictive performance in these three methods. The model comparisons showed that the ANN models of disease-free survival obtained superior AUROC values and have potential applications in decision support systems used to assess the need for hepatic resection in HCC patients.

In conclusion, comparison of prediction models for 1-, 3- and 5-year disease-free survival in HCC patients who have received hepatic resection revealed that the prediction models obtained by ANN machine learning method were superior to those obtained by conventional LR and DT. The AUROC values in the ANN models were generally higher than those in LR and DT models. That is, The ANN model had superior predictive accuracy. Therefore, this study demonstrated the feasibility of applying ANN in medical decision support systems that use clinical databases to predict disease-free survival in HCC patients who have received hepatic resection. Physicians may also consider machine-learning methods as a supplemental tool for clinical decision-making and prognostic evaluation.
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